Board of Directors

Vanessa Jacoby brings financial expertise along with extensive experience in the biotechnology and life science sectors to Sonoma's Board. She has served as a senior financial executive of several private and public companies and as an active participant on audit committees, responsible for reporting financial results and internal controls matters. Prior to joining Quanta, a clinical stage biotechnology company, Ms. Jacoby served as CFO of Shoreline Biosciences, where she played a key role in establishing two partnerships with Kite Pharma and BeiGene. Prior to joining Shoreline, Ms. Jacoby served as Chief Accounting Officer of Avidity Biosciences, Inc. (NASDAQ: RNA), where she led all corporate finance and planning activities and played a key role in the company's initial public offering. Ms. Jacoby is a licensed CPA in the State of California and began her career as an auditor for Ernst & Young.

Mr. McLaughlin served as Interim Chief Executive Officer of Applied BioCode, Inc. from November 2011 to April 2013. In April 2011, he also founded and currently serves as Chairman and Chief Executive Officer, of DataStream Medical Imaging Systems, Inc., a start-up to develop diagnostic imaging software applications that work in conjunction with existing digital radiology platforms. He previously served as President of DataFlow Information Systems, from July 2007 to December 2011, and President and Chief Executive Officer of CompuMed, Inc. from May 2002 to June 2007. Mr. McLaughlin also serves on the board of directors of DataStream Medical Imaging Systems, Inc., a private company in the medical imaging software industry.

Amy Trombly is our Chief Executive Officer and also serves on our Board of Directors. She counseled public companies for two decades in corporate and securities law and mergers and acquisitions as the owner and manager of Trombly Business Law, PC. In her earlier career, Ms. Trombly was a Vice President at State Street Bank and Special Counsel at the U.S. Securities and Exchange Commission. Ms. Trombly is a member of the bar in Massachusetts and Colorado.

Mr. Weigerstorfer brings extensive pharmaceutical and dermatology experience to Sonoma's board with a track record of expanding businesses around the globe. He began his career in marketing at Sandoz and Novartis, advancing to marketing and business leader roles for cardiovascular, dermatology and other global business units. During this time, he helped develop and launch highly successful brands such as Lamisil, Apligraf and Elidel. In 1999, Weigerstorfer joined Galencia Ltd's executive team where he led the retail, pre-wholesale, business development and M&A divisions. Philippe was a key leader in transforming Galencia from a Swiss-based wholesaler to a player in the international healthcare market.